Our Mission

To discover novel therapeutics that will stop the progression
of neurodegenerative diseases by targeting their underlying causes.

Our Programs

NPT520-34 Phase 1 in Healthy Volunteers
UCB0599 Phase 1b in PD Patients


UCB Initiates Phase 1b US-Based Multicenter Clinical Trial in Parkinson's Disease Patients with UCB0599, a Compound Arising from the Neuropore-UCB Collaboration May 28, 2019

Neuropore Therapies, Inc. announced today that partner UCB initiated a multicenter clinical trial in Parkinson's disease patients with UCB0599 in the United States of America. UCB0599, an alpha-synuclein misfolding inhibitor, is a therapeutic candidate arising from the Neuropore-UCB collaboration. Neuropore will receive a $5 million (USD) award as a result of achieving this milestone.

See All News

NPT® Publications

Neuropore publishes paper describing the preclinical in vivo characterization of a small molecule compound targeting α-synuclein as a potential Parkinson's disease therapeutic
November 2nd, 2018

Report in Scientific Reports, describes the beneficial effects of NPT200-11 on multiple disease relevant endpoints in a transgenic mouse model of Parkinson's disease.

See All Publications



A team poised for success

About Our Team

Our Partners


UCB Logo

Foundations & Academic InstitutionsSEE ALL

The Michael J. Fox Foundation for Parkinson's Research
Albert Einstein College of Medicine
University of Sydney

Connect with Neuropore